美國居民不適用 XM 服務。

Indian health insurer Niva Bupa files for $360 mln IPO



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Indian health insurer Niva Bupa files for $360 mln IPO</title></head><body>

Adds details on IPO, company from paragraph 2 onwards

BENGALURU, July 1 (Reuters) -Indian health insurer Niva Bupa has filed for an initial public offering (IPO) to raise up to 30 billion rupees (nearly $360 million), draft papers showed on Monday.

The company, majority owned by British United Provident Fund (Bupa), said it will issue fresh shares worth up to eight billion rupees as part of the offering.

It aims to use the proceeds from that sale to strengthen its balance sheet and for operating expenses.

Existing shareholders Bupa Singapore Holdings and Fettle Tone, will sell shares up to 22 billion rupees, Niva Bupa added.

As of the end of fiscal 2024, the company's borrowings stood at 2.50 billion rupees, unchanged for the third straight fiscal. Its total income, which comprises net premium income, investment income and other income, rose 44% year-on-year.

ICICI Securities, Morgan Stanley, Kotak Mahindra Capital and Axis Capital were among the book-running managers to Niva Bupa's IPO.

The insurer is set to go public in India's booming IPO market.

More than 100 companies have raised around $4 billion in IPOs so far this year, more than double the amount raised by this time last year, per LSEG data, with the domestic equity market at an all-time high on the prospect of healthy economic growth.


($1 = 83.3950 Indian rupees)



Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala and Nivedita Bhattacharjee

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明